2009
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
Pavlick AC, Wu J, Roberts J, Rosenthal MA, Hamilton A, Wadler S, Farrell K, Carr M, Fry D, Murgo AJ, Oratz R, Hochster H, Liebes L, Muggia F. Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer Chemotherapy And Pharmacology 2009, 64: 803. PMID: 19221754, PMCID: PMC3901370, DOI: 10.1007/s00280-009-0931-y.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsPhase INon-hematologic tumorsPhase II dosesPhase II doseDose-limiting toxicityResultsFifty-three patientsBlood mononuclear cellsNon-hematologic malignanciesBryostatin 1Cytotoxicity of cisplatinCisplatin 50PurposePreclinical dataObjective responseContinuous infusionMononuclear cellsTolerable dosesProtein kinase C modulatorsCisplatin effectComputerized tomographyPatientsConsistent inhibitionCisplatin cytotoxicityCisplatinMinimal toxicity
2003
RTOG 97-06: Initial report of a Phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy
Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU. RTOG 97-06: Initial report of a Phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 2003, 57: 665-672. PMID: 14529770, DOI: 10.1016/s0360-3016(03)00718-1.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellChemotherapy, AdjuvantCisplatinCombined Modality TherapyConfidence IntervalsCystectomyFemaleHumansMaleMethotrexateMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingRadiation-Sensitizing AgentsRadiotherapyRemission InductionUrinary Bladder NeoplasmsVinblastineConceptsGrade 3 toxicityAdjuvant chemotherapyInduction therapyOverall survivalResidual diseaseAdditional adjuvant chemotherapyBladder-sparing treatmentCycles of methotrexateGrade 4 hydronephrosisGrade 4 neutropeniaSelective bladder conservationEvidence of diseaseClinical T stagePositive cytologic findingsAggressive transurethral resectionRTOG 97Surgery specimenKarnofsky scoreLocoregional controlLocoregional failureCombination cisplatinMost patientsPathologic reviewProtocol treatmentVinblastine chemotherapy
1999
Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines
Roberts J, Peroutka J, Beggiolin G, Manzotti C, Piazzoni L, Farrell N. Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines. Journal Of Inorganic Biochemistry 1999, 77: 47-50. PMID: 10626353, DOI: 10.1016/s0162-0134(99)00137-3.Peer-Reviewed Original ResearchConceptsPolynuclear platinum complexesPlatinum complexesDiamine linkerL1210 cell lineDinuclear platinum complexesTrinuclear platinum complexL1210 murine leukemia cell lineL1210/DDPDinuclear complexesAnticancer profileChemical featuresCytotoxicity profileCellular uptakeBBR3464LinkerMurine leukemia cell lineComplexesTransCharge contributesClinical agentsCytotoxicityUptake pathwayCellular accumulationAntitumor activityPlatinumCellular pharmacology of polynuclear platinum anti-cancer agents
Roberts J, Peroutka J, Farrell N. Cellular pharmacology of polynuclear platinum anti-cancer agents. Journal Of Inorganic Biochemistry 1999, 77: 51-57. PMID: 10626354, DOI: 10.1016/s0162-0134(99)00147-6.Peer-Reviewed Original ResearchConceptsCisplatin-resistant cell linesCell linesCross-linking adductsWild-type cell linesDNA repair mechanismsL1210 murine leukemia cell lineCellular pharmacologyType cell linesGenomic accessMurine leukemia cell lineWild typeCytotoxic effectsLeukemia cell linesRepair mechanismsDNA interstrandAnti-cancer agentsDiminished accumulationDinuclear platinum complexesTrinuclear platinum complexBBR3464Enhanced activityPotential anticancer agentsPotent cytotoxic agentComplexesVivo activity
1989
Interaction of novel bis(platinum) complexes with DNA
Roberts J, Van Houten B, Qu Y, Farrell N. Interaction of novel bis(platinum) complexes with DNA. Nucleic Acids Research 1989, 17: 9719-9733. PMID: 2690006, PMCID: PMC335209, DOI: 10.1093/nar/17.23.9719.Peer-Reviewed Original Research